European Commission approves Sunosi® (solriamfetol)
EU marketing authorisation has been given to Sunosi (solriamfetol) for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea.
List view / Grid view
EU marketing authorisation has been given to Sunosi (solriamfetol) for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea.
The EMA CHMP has revealed its suggestion to grant marketing authorisation to seven medicines after its most recent meeting.